Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225456 | 0.83 | NPC1 (0.47) | DRD2DRD4DRD3ALDH1A1LMNA | |
| SCHEMBL2221076 | 0.83 | LMNA (0.49) | ALDH1A1LMNAKMT2AHDAC1HDAC8 | |
| SCHEMBL2224617 | 0.83 | HDAC1 (0.44) | DRD2DRD4DRD3ALDH1A1LMNA | |
| SCHEMBL10942728 | 0.83 | DRD2 (0.50) | DRD2DRD4DRD3ALDH1A1FFAR1 | |
| SCHEMBL2225613 | 0.82 | FFAR1 (0.47) | FFAR1LMNANOTUM | |
| SCHEMBL6976762 | 0.82 | NPC1 (0.45) | ALDH1A1ENPP3LMNAKMT2AMEN1 | |
| SCHEMBL2225747 | 0.80 | ENPP3 (0.50) | ALDH1A1ENPP3ENPP1KMT2AMEN1 | |
| SCHEMBL2225025 | 0.79 | KDM4E (0.43) | ALDH1A1KMT2AMEN1MAPTNOTUM | |
| SCHEMBL6964586 | 0.79 | HDAC1 (0.48) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL28619274 | 0.79 | HPGD (0.47) | ALDH1A1LMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| EP-3393458-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GlaxoSmithKline LLC (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112838-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112838-A1 | METHODS OF USE OF A CLASS llA HDAC INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | DRD2 1466/4885DRD4 608/4885DRD3 304/4885 |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | HDAC7, HDAC8, HDAC5 | DRD2 4803/4885DRD4 4843/4885DRD3 4815/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | DRD2 1466/4885DRD4 608/4885DRD3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.